Analyst Price Targets — CTNM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 11:19 am | — | Morgan Stanley | $14.00 | $9.56 | TheFly | Contineum downgraded to Equal Weight from Overweight at Morgan Stanley |
| November 24, 2025 12:33 pm | — | Robert W. Baird | $14.00 | $10.95 | TheFly | Contineum price target lowered to $14 from $16 at Baird |
| November 21, 2025 1:42 pm | Brian Abrahams | RBC Capital | $22.00 | $12.22 | TheFly | Contineum price target lowered to $22 from $25 at RBC Capital |
| September 25, 2025 10:06 am | — | Leerink Partners | $20.00 | $10.86 | TheFly | Contineum initiated with an Outperform at Leerink |
| March 7, 2025 12:33 pm | — | Robert W. Baird | $16.00 | $6.77 | TheFly | Contineum price target lowered to $16 from $32 at Baird |
| October 21, 2024 4:54 pm | Joel Beatty | Robert W. Baird | $32.00 | $16.07 | StreetInsider | Baird Starts Contineum Therapeutics (CTNM) at Outperform |
| April 30, 2024 4:46 am | Brian Abrahams | RBC Capital | $30.00 | $16.00 | TheFly | Contineum initiated with an Outperform at RBC Capital |
| April 30, 2024 2:35 am | Paul Matteis | Stifel Nicolaus | $29.00 | $16.00 | StreetInsider | Stifel Starts Contineum Therapeutics (CTNM) at Buy |
Latest News for CTNM
Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of…
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. “We're off to a strong start in 2026, having…
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.…
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTNM.
U.S. House Trading
No House trades found for CTNM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.